BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GEN-725 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GEN-725\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07362940-2490@assetmemo.bio
DTSTAMP:20261121T005444Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:GEN-725: Phase 1/2 readout est. (NCT07362940)
DESCRIPTION:GEN-725\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib\nEstim
 ated primary completion: 31 July 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/gen-725#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07362940
URL:https://assetmemo.bio/drug/gen-725#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
